MARKETS
Earnings

Harvard Bioscience Sees Q3 Sales $21.000M-$22.600M vs $21.850M Est

Aug 11, 2026 · 07:03 AM ET· updated 1h ago

Harvard Bioscience (NASDAQ:HBIO) sees Q3 sales of $21.000 million-$22.600 million vs $21.850 million analyst estimate.

Share
Why It Matters

Harvard Bioscience says its sales next quarter might be a bit lower than experts expected. When a company's forecast comes in lower than predictions, investors watch to see if the business is slowing down or just being careful with its numbers.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.